when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
drugs
LOSARTAN POTASSIUM

drug

LOSARTAN POTASSIUM

Marketedupdated 3mo ago

by $SCNX Scienture Holdings, Inc.

Approved

community read0 votes

🐶 often sniffed alongside

top 8

tagApproval238 co-mentions · 119 sources
drugALDACTAZIDE156 co-mentions · 78 sources
drugARBLI121 co-mentions · 119 sources
tagSmall Molecule119 co-mentions · 119 sources
drugLOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE78 co-mentions · 78 sources
companyAurobindo Pharma Ltd15 co-mentions · 15 sources
companyLupin Ltd14 co-mentions · 14 sources
companyMicro Labs Ltd9 co-mentions · 9 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 6 investigational indications.

indications

investigational

Hypertension

all catalysts(29)

approval · 29

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

$SCNX0.3314-4.08%

ARBLI (LOSARTAN POTASSIUM) — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

$SCNX0.3314-4.08%

ARBLI (LOSARTAN POTASSIUM) — FDA approval

LOSARTAN POTASSIUM

LOSARTAN POTASSIUM — FDA approval

LOSARTAN POTASSIUM

view all 29 catalysts →

Trials studying LOSARTAN POTASSIUM

phase1Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditionscompletedn=80
phase4Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)completedn=120
phase4ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)completedn=367
phase3Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)completedn=62
phase4Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)completedn=174
phase3HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)completedn=312
phase3An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)terminatedn=11
phase3MK0954A-264 Filter Study (0954A-264)(COMPLETED)completedn=274

more trials →

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 7, 2041

~15.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

Oct 7, 2041formulationUS 11890273
Oct 7, 2041formulationUS 12156869

News(0)

no news has mentioned this drug yet

brand

LOSARTAN POTASSIUM

generic

LOSARTAN POTASSIUM

MOA

12.1 Mechanism of Action Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor found in many tissues, (e.g., vascular smooth muscle, adrenal gland). There is also an AT 2 receptor found in many tissues, but it is not known to be associated with cardiovascular homeostasis. Neither losartan nor its principal active metabolite exhibits any partial agonist activity at the AT 1 receptor, and both have much greater affinity (about 1,000-fold) for the AT 1 receptor than for the AT 2 receptor. In vitro binding studies indicate that losartan is a reversible, competitive inhibitor of the AT 1 receptor. The active metabolite is 10 to 40 times more potent by weight than losartan and appears to be a reversible, noncompetitive inhibitor of the AT 1 receptor. Neither losartan nor its active metabolite inhibits ACE (kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin), nor do they bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.

indication

Hypertension

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 20m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?